Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following two offers if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
JOIN THE CLUB
Canadian Insider Ad-Free
$49/ year*
All benefits of basic registration
No 3rd party display ads
10-day money back guarantee*
GO AD-FREE

* Price is subject to applicable taxes. Money back guarantee: For bona fide Ad-Free or Canadian Insider Club subscribers, if you downgrade to Basic or cancel with-in 10 days of first subscribing, we will refund your payment upon request. Immediately after downgrading or cancelling, using the same email that is associated with your account, request a refund via our Contact Us form at the bottom of the page. We will only consider one refund request per household or organization. We cannot accommodate refund requests where an account holder has not provided verifiable address and billing information.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Acasti Pharma Inc. (V:ACST)

Business Focus: Pharmaceuticals

INK Edge Outlook

Log in or join to add this stock to your watch list.

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for ACST within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Apr 15, 2019 09:15 ET
Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia
Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment...
Read full article
Apr 01, 2019 09:20 ET
Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal
Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.90
--
--
Price to Sales - TTM
--
11.77
19.21
Price to Book - most recent quarter
3.19
2.91
3.45
Price to Cash Flow per share - TTM
--
9.90
11.72
Price to Free Cash Flow per share - TTM
--
11.95
14.63
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Mar 31, 2019126,262-51,992
Mar 15, 2019178,25472,593
Feb 28, 2019105,661-49,753
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG). The Company's drug candidate is CaPre, an OM3 phospholipid, which is being developed for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream (over 500 mg/dL) (severe hypertriglyceridemia or severe HTG).

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $ACST.CA ACST.V

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $ACST.CA ACST.V